ES2572215T3 - Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico - Google Patents

Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico

Info

Publication number
ES2572215T3
ES2572215T3 ES12729030T ES12729030T ES2572215T3 ES 2572215 T3 ES2572215 T3 ES 2572215T3 ES 12729030 T ES12729030 T ES 12729030T ES 12729030 T ES12729030 T ES 12729030T ES 2572215 T3 ES2572215 T3 ES 2572215T3
Authority
ES
Spain
Prior art keywords
mat3
prolactin receptor
antibody against
therapeutic use
neutralizing antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12729030T
Other languages
English (en)
Inventor
Christoph Freiberg
Christiane Otto
Lars Linden
Axel Harrenga
Mark Trautwein
Simone Greven
Andreas Wilmen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Application granted granted Critical
Publication of ES2572215T3 publication Critical patent/ES2572215T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

El anticuerpo Mat3 o fragmentos de unión a antígeno del mismo, que antagonizan la señalización mediada por el receptor de prolactina, en el que el anticuerpo o los fragmentos de unión a antígeno comprenden a. una región variable pesada con una secuencia de aminoácidos de acuerdo con la SEQ ID NO: 1, y b. una región variable ligera con una secuencia de aminoácidos de acuerdo con la SEQ ID NO: 2.
ES12729030T 2011-06-03 2012-05-31 Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico Active ES2572215T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11168644A EP2530089A1 (en) 2011-06-03 2011-06-03 Neutralising prolactin receptor antibody Mat3 and its therapeutical use
PCT/EP2012/060078 WO2012163932A1 (en) 2011-06-03 2012-05-31 Neutralizing prolactin receptor antibody mat3 and its therapeutic use

Publications (1)

Publication Number Publication Date
ES2572215T3 true ES2572215T3 (es) 2016-05-30

Family

ID=46331236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12729030T Active ES2572215T3 (es) 2011-06-03 2012-05-31 Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico

Country Status (37)

Country Link
US (2) US9353186B2 (es)
EP (2) EP2530089A1 (es)
JP (1) JP5859641B2 (es)
KR (1) KR101920521B1 (es)
CN (1) CN103764679B (es)
AP (1) AP2013007266A0 (es)
AR (1) AR086631A1 (es)
AU (1) AU2012264765B2 (es)
BR (1) BR112013030995B1 (es)
CA (1) CA2837736C (es)
CL (1) CL2013003459A1 (es)
CO (1) CO6852025A2 (es)
CR (1) CR20130632A (es)
CU (1) CU20130163A7 (es)
CY (1) CY1117660T1 (es)
DK (1) DK2714740T3 (es)
DO (1) DOP2013000285A (es)
EA (1) EA029316B1 (es)
EC (1) ECSP13013063A (es)
ES (1) ES2572215T3 (es)
HR (1) HRP20160506T1 (es)
HU (1) HUE028775T2 (es)
IL (1) IL229504B (es)
MA (1) MA35237B1 (es)
ME (1) ME02659B (es)
MX (1) MX343683B (es)
PE (1) PE20141158A1 (es)
PH (1) PH12013502494A1 (es)
PL (1) PL2714740T3 (es)
RS (1) RS54727B1 (es)
SG (1) SG195060A1 (es)
SI (1) SI2714740T1 (es)
TN (1) TN2013000501A1 (es)
TW (1) TWI548649B (es)
UY (1) UY34116A (es)
WO (1) WO2012163932A1 (es)
ZA (1) ZA201309683B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361875B (es) 2012-03-14 2018-12-18 Regeneron Pharma Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
CN105102480B (zh) * 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
PE20200481A1 (es) 2017-07-10 2020-03-03 Bayer Pharma AG Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos
KR102631281B1 (ko) * 2017-08-10 2024-01-30 그리폴스 다이어그노스틱 솔루션즈 인크. 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4428150A1 (en) 2023-03-07 2024-09-11 Peptide Logic LLC Antibody or antigen-binding fragment thereof
CN116655791B (zh) * 2023-05-06 2023-11-07 浙江触奇生物科技有限公司 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用
CN120388750B (zh) * 2025-04-15 2025-12-09 绵阳市妇幼保健院(绵阳市儿童医院) 一种子宫内膜异位症患者哺乳期复查随访数据处理系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
AR062435A1 (es) * 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use

Also Published As

Publication number Publication date
IL229504A0 (en) 2014-01-30
SG195060A1 (en) 2013-12-30
US9353186B2 (en) 2016-05-31
ZA201309683B (en) 2016-08-31
CU20130163A7 (es) 2014-04-24
MA35237B1 (fr) 2014-07-03
US9777063B2 (en) 2017-10-03
US20140141003A1 (en) 2014-05-22
HRP20160506T1 (hr) 2016-06-17
CL2013003459A1 (es) 2014-08-08
ME02659B (me) 2017-06-20
CO6852025A2 (es) 2014-01-30
TN2013000501A1 (en) 2015-03-30
HK1195081A1 (zh) 2014-10-31
AR086631A1 (es) 2014-01-08
CR20130632A (es) 2014-02-04
US20160319029A1 (en) 2016-11-03
MX2013014174A (es) 2014-11-13
BR112013030995B1 (pt) 2021-11-09
EP2714740A1 (en) 2014-04-09
TW201302798A (zh) 2013-01-16
AU2012264765A1 (en) 2013-12-19
KR101920521B1 (ko) 2018-11-21
IL229504B (en) 2018-10-31
BR112013030995A2 (pt) 2016-11-22
ECSP13013063A (es) 2014-01-31
TWI548649B (zh) 2016-09-11
PE20141158A1 (es) 2014-09-26
AP2013007266A0 (en) 2013-11-30
WO2012163932A1 (en) 2012-12-06
KR20140036275A (ko) 2014-03-25
PL2714740T3 (pl) 2016-08-31
JP5859641B2 (ja) 2016-02-10
EA029316B1 (ru) 2018-03-30
CN103764679A (zh) 2014-04-30
EA201301356A1 (ru) 2014-09-30
DK2714740T3 (da) 2016-05-30
CA2837736A1 (en) 2012-12-06
MX343683B (es) 2016-11-17
CN103764679B (zh) 2016-05-04
CA2837736C (en) 2018-11-20
RS54727B1 (sr) 2016-10-31
EP2714740B1 (en) 2016-03-30
NZ618316A (en) 2016-01-29
AU2012264765B2 (en) 2016-07-28
DOP2013000285A (es) 2014-03-16
PH12013502494A1 (en) 2014-01-20
JP2014522239A (ja) 2014-09-04
CY1117660T1 (el) 2017-05-17
UY34116A (es) 2013-01-03
HUE028775T2 (en) 2017-01-30
EP2530089A1 (en) 2012-12-05
SI2714740T1 (sl) 2016-06-30

Similar Documents

Publication Publication Date Title
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
ECSP13013097A (es) Coagonistas del receptor de glucagón/glp-1
CL2018003597A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20161152A1 (es) Anticuerpos y metodos de uso
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX2017006626A (es) Cadenas ligeras comunes y metodos de uso.
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201691991A1 (ru) Мультиспецифические антитела
CR20110553A (es) Terapia complementaria contra el cáncer
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
CL2016002245A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.